New national standards arrive but unequal screening access and a deadly racial gap still shape who lives and who doesn't
Where a Canadian woman lives — and what she looks like — can determine whether she survives breast cancer.
For the first time, Canada’s leading breast cancer experts have released national treatment standards, filling a gap that has long produced uneven care plans and patient outcomes across provinces.
The REAL Canadian Breast Cancer Alliance published the consensus recommendations in Current Oncology, covering all major subtypes: HER2+, HR+ early and advanced stage, triple-negative, and clinical staging.
The Alliance, established by Breast Cancer Canada in 2023, drew on clinical data from major international conferences including ESMO, ASCO, and the San Antonio Breast Cancer Symposium.
“No patient’s outcome should depend on their postal code,” said Mita Manna, chair of the REAL Canadian Breast Cancer Alliance and medical oncologist at the Saskatchewan Cancer Centre.
A national poll by Breast Cancer Canada found 92 percent of Canadians said they would trust such guidelines if developed by a coalition of top experts grounded in evidence and patient needs.
The stakes are clear.
Statistics Canada data shows the five-year survival rate for Stage 1 breast cancer sits at 99.8 percent — a figure that collapses to 23 percent by Stage 4.
Yet access to early detection has varied widely depending on province.
Alberta recently announced it will lower the self-referral mammogram age from 45 to 40, making more than 193,000 additional women eligible for screening, CBC News reported.
But the change does not take effect until April 2027 — a delay the province says is needed to prepare the health system for increased demand.
Advocates are pushing back.
“So much suffering can be avoided,” said Jennie Dale, founder of Dense Breasts Canada. “I’m hoping perhaps they’ll change their mind, not wait.”
When Alberta does lower the age, it will be among the last to do so.
Most provinces have already moved: Manitoba plans to lower its self-referral age from 45 to 40 by year-end; Saskatchewan dropped it to 43 this year and plans to reach 40 within months.
Quebec still starts screening at 50.
Early detection, advocates note, also reduces costs for the health system — cutting hospital visits, ongoing treatment expenses, and pressure on oncologists who already face long waitlists.
Natalie Kwadrans, a Calgary mother of two, was too young to qualify for a screening mammogram in Alberta when she found a lump in her early 40s.
By the time she was diagnosed — shortly after her 46th birthday — the cancer had spread to her sternum, a rib, and her spine.
Seven years on, she has been through chemotherapy, immunotherapy, radiation, emergency surgery, and multiple ER visits.
The cancer has progressed again; she will be on chemotherapy for the rest of her life.
“Cancer doesn’t care what province you live in,” she told CBC News. “Cancer decided I was not too young.”
The national standards and screening age shifts also arrive against a troubling backdrop of racial disparity.
A study reported by CTV News found Black women in Canada face up to 70 percent higher breast cancer death rates than white women — with Black women of Caribbean origins facing a 70 percent higher death rate at ages 40 to 49 and a 42 percent higher rate between ages 50 to 59.
The average age of death for Black women was 53 to 66, compared to 71 for white women.
More than half of breast cancer cases in Black women were diagnosed before age 50, compared to about 14 percent in white women, and they face up to 21 percent higher rates of triple-negative breast cancer — compared to roughly 9.9 percent for white women.
Aisha Lofters, a clinician scientist at Women’s College Hospital in Toronto and co-author of the study, said the goal is “risk-based” breast cancer screening tailored to the individual — and the findings suggest ancestry should be part of that calculation.
